Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Opdivo’s NHI Price-Based Sales Put at Over 151 Billion Yen; 50% Cut Likely to Take Effect Feb. 1
November 15, 2016
- MHLW Advisory Committee to Review Biogen’s MS Drug on Nov. 25
November 14, 2016
- Opdivo Gets MHLW Panel Nod for Hodgkin’s Lymphoma
November 14, 2016
- MHLW Panel to Discuss NSCLC Indication for Keytruda on Nov. 24
November 14, 2016
- LDP Study Group on Biologics to Hold 1st Meeting on Nov. 24; Aims to Halt the Rush to Promote Biosimilars
November 11, 2016
- Chuikyo Members Chide Unexplained Withdrawal of Taltz’s Listing Request
November 10, 2016
- MHLW Won’t Require Use of Other Psoriasis Drugs before Taltz
November 10, 2016
- MHLW Plans 50% Price Cut for Opdivo
November 10, 2016
- Chuikyo OKs Taltz, Micatrio for Listing on Nov. 18; Keytruda Takes Pass This Time
November 9, 2016
- LDP Lawmakers Discuss Re-Pricing of Opdivo; Some Say Application of Huge Seller Rule Reasonable
November 9, 2016
- Shiozaki Lauds BIKEN-Mitsubishi Vaccine JV
November 8, 2016
- PMDA Fastest in Granting New Drug Approvals
November 4, 2016
- PMDA Mulls Fee Raise for Drug, Device Reviews
November 4, 2016
- Medical Corporation in Tokyo Ordered to Temporarily Suspend Regenerative Medicine Service: MHLW
November 4, 2016
- MHLW Struggling to Set Date for Chuikyo Subcommittee Discussions on Opdivo
November 2, 2016
- MHLW Panel Backs Ono’s Hyperparathyroidism Drug Etelcalcetide
November 1, 2016
- PMDA Had 71 Individual Interviews in Regulatory Strategy Consultation Services in April-September 2016
November 1, 2016
- Inisync, 4 Other DPP-4 Inhibitors Under PMDA Risk Review
October 31, 2016
- Postponed PAFSC 2nd Committee Meeting Set for November 11
October 31, 2016
- MID-NET Working Group Discusses Access Fee Calculations
October 28, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…